FDA approves twice-yearly HIV prevention injection
npr.org —
The FDA approved lenacapavir, a twice-yearly injection for HIV prevention, offering protection comparable to daily pills and hailed as a breakthrough. This approval marks a significant advancement in HIV prevention strategies. Clinical trials showed lenacapavir to be highly effective, with near-complete protection in some studies. However, the drug's high cost, approximately $28,000 annually, raises concerns about accessibility, particularly in lower-resource countries with high HIV burdens. While Gilead Sciences is working to broaden access through licensing agreements, funding cuts and high prices could limit the drug's impact. The availability and affordability of lenacapavir will be crucial for its global effectiveness.